Amgen Becomes A Biotech Safety Stock (AMGN)

Health and Healthcare

Published: October 22, 2008 3:15 pm

Last Updated: April 27, 2020 3:52 pm

Amgen_logo Amgen Inc. (NASDAQ: AMGN) has just posted earnings. The biotech giant for anemia treatments posted $1.09 GAAP EPS and adjusted earnings of $1.23 non-GAAP EPS and $3.875 billion in revenues. First Call had estimates pegged at $1.08 EPS on revenues of $3.7 billion.

The company has also now raised full-year guidance to $4.45 to $4.55EPS from the prior range of $4.25 to $4.45 EPS. First call hasestimates at $4.38 EPS.

Aranesp sales were up at $845 million and it saw $634 million in Epogen sales, both of which were above estimates.

Shares closed down over 4.7% at $49.92 for an unofficial closing price,but shares are flying high up around the $53.00 mark in after-hourstrading. The 52-week trading range is $39.16 to $66.51.

Jon C. Ogg
October 22, 2008

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!